CMAJ • December 8, 2009; 181 (12). First published November 23, 2009; doi:10.1503/cmaj.090917
© 2009 Canadian Medical Association or its licensors
All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.
This Article
Right arrow Abstract
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Online Appendix
Right arrow Submit a response
Right arrow View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by McAlister, F. A.
Right arrow Articles by Grimshaw, J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by McAlister, F. A.
Right arrow Articles by Grimshaw, J.
Related Collections
Right arrowRelated Article

The Enhancing Secondary Prevention in Coronary Artery Disease trial

Finlay A. McAlister, MD MSc, Miriam Fradette, BSc Pharm, Sumit R. Majumdar, MD MPH, Randall Williams, MD, Michelle Graham, MD, James McMeekin, MD, William A. Ghali, MD MPH, Ross T. Tsuyuki, PharmD MSc, Merril L. Knudtson, MD and Jeremy Grimshaw, MB ChB PhD

From the Department of Medicine (McAlister, Majumdar, Graham, Tsuyuki), University of Alberta; the Epidemiology Coordinating and Research Centre (McAlister, Fradette, Majumdar, Graham, Tsuyuki), University of Alberta; the Mazankowski Alberta Heart Institute (McAlister, Graham, Tsuyuki), University of Alberta; the Royal Alexandra Hospital (Williams), Edmonton, Alta.; the Department of Medicine (McMeekin, Ghali, Knudtson), University of Calgary, Calgary, Alta.; and the University of Ottawa Health Research Unit (Grimshaw), Ottawa, Ont.


View this table:
[in this window]
[in a new window]

  		Table 1: Characteristics at the time of cardiac catheterization of patients included in the Enhancing Secondary Prevention in Coronary Artery Disease trial

 

Figure 16
View larger version (29K):
[in this window]
[in a new window]

  		Figure 1: Selection and randomization of patients included in the Enhancing Secondary Prevention in Coronary Artery Disease (ESP-CAD) trial. LDL = low-density lipoprotein, CABG = coronary artery bypass graft.

 

View this table:
[in this window]
[in a new window]

  		Table 2: Outcomes 6 months after cardiac catheterization

 

Figure 26
View larger version (31K):
[in this window]
[in a new window]

  		Figure 2: Improvement in statin management (initiation of a statin or doseage increase) 6 months after cardiac catheterization in subgroups. The median low-density lipoprotein (LDL) cholesterol level at baseline was 2.9 mmol/L.